Desglymidodrine: Difference between revisions

Latest revision as of 11:05, 15 February 2025

Desglymidodrine[edit]

Desglymidodrine is a pharmacologically active metabolite of the prodrug midodrine, which is used primarily in the treatment of orthostatic hypotension. Desglymidodrine is an alpha-adrenergic agonist, meaning it stimulates alpha-adrenergic receptors, leading to vasoconstriction and an increase in blood pressure.

Pharmacology[edit]

Desglymidodrine is formed in the body from midodrine through enzymatic hydrolysis. Once converted, desglymidodrine exerts its effects by selectively activating alpha-1 adrenergic receptors located on the smooth muscle cells of blood vessels. This activation causes the blood vessels to constrict, thereby increasing peripheral vascular resistance and elevating blood pressure.

Mechanism of Action[edit]

The primary action of desglymidodrine is its ability to bind to and activate alpha-1 adrenergic receptors. These receptors are part of the sympathetic nervous system and are responsible for mediating vasoconstriction. By activating these receptors, desglymidodrine increases the tone of the vascular smooth muscle, leading to increased blood pressure.

Clinical Use[edit]

Desglymidodrine, through its prodrug midodrine, is used in the management of orthostatic hypotension, a condition characterized by a significant drop in blood pressure upon standing. This condition can lead to dizziness, lightheadedness, and even fainting. By increasing blood pressure, desglymidodrine helps to alleviate these symptoms and improve the quality of life for affected individuals.

Side Effects[edit]

The use of desglymidodrine can lead to several side effects, primarily due to its vasoconstrictive properties. Common side effects include:

Patients are advised to monitor their blood pressure regularly to avoid excessive hypertension.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-= Desglymidodrine =
+== Desglymidodrine ==
-'''Desglymidodrine''' is a pharmacologically active metabolite of the prodrug [[midodrine]], which is used primarily in the treatment of orthostatic hypotension. It is an alpha-1 adrenergic receptor agonist that causes vasoconstriction, thereby increasing blood pressure.
+[[File:Desglymidodrine.svg|thumb|right|Chemical structure of Desglymidodrine]]
+'''Desglymidodrine''' is a pharmacologically active metabolite of the prodrug [[midodrine]], which is used primarily in the treatment of [[orthostatic hypotension]]. Desglymidodrine is an [[alpha-adrenergic agonist]], meaning it stimulates alpha-adrenergic receptors, leading to vasoconstriction and an increase in blood pressure.
 == Pharmacology ==
-Desglymidodrine is the active form of midodrine, which is converted in the liver. Once administered, midodrine is rapidly absorbed and undergoes enzymatic hydrolysis to form desglymidodrine. This conversion is crucial for its therapeutic effects, as desglymidodrine is responsible for the vasopressor activity.
-=== Mechanism of Action ===
+Desglymidodrine is formed in the body from midodrine through enzymatic hydrolysis. Once converted, desglymidodrine exerts its effects by selectively activating alpha-1 adrenergic receptors located on the smooth muscle cells of blood vessels. This activation causes the blood vessels to constrict, thereby increasing peripheral vascular resistance and elevating blood pressure.
-Desglymidodrine acts by stimulating alpha-1 adrenergic receptors located on the smooth muscle cells of blood vessels. This stimulation leads to vasoconstriction, which increases peripheral vascular resistance and subsequently elevates blood pressure. This mechanism is particularly beneficial in patients with orthostatic hypotension, where blood pressure drops significantly upon standing.
+== Mechanism of Action ==
+The primary action of desglymidodrine is its ability to bind to and activate [[alpha-1 adrenergic receptors]]. These receptors are part of the [[sympathetic nervous system]] and are responsible for mediating vasoconstriction. By activating these receptors, desglymidodrine increases the tone of the vascular smooth muscle, leading to increased blood pressure.
 == Clinical Use ==
-Desglymidodrine, through its prodrug midodrine, is indicated for the treatment of symptomatic orthostatic hypotension. It helps in reducing symptoms such as dizziness, lightheadedness, and fainting by maintaining adequate blood pressure levels when a person stands up.
-== Pharmacokinetics ==
+Desglymidodrine, through its prodrug midodrine, is used in the management of [[orthostatic hypotension]], a condition characterized by a significant drop in blood pressure upon standing. This condition can lead to dizziness, lightheadedness, and even fainting. By increasing blood pressure, desglymidodrine helps to alleviate these symptoms and improve the quality of life for affected individuals.
-After oral administration of midodrine, it is rapidly absorbed and converted to desglymidodrine. The peak plasma concentration of desglymidodrine is typically reached within 1 to 2 hours. The elimination half-life of desglymidodrine is approximately 3 to 4 hours, which necessitates multiple dosing throughout the day to maintain its therapeutic effect.
 == Side Effects ==
-Common side effects associated with desglymidodrine include:
-* Supine hypertension
-* Piloerection (goosebumps)
-* Pruritus (itching)
-* Urinary retention
-Patients are advised to monitor their blood pressure regularly and report any significant increases, especially when lying down, as this can lead to supine hypertension.
+The use of desglymidodrine can lead to several side effects, primarily due to its vasoconstrictive properties. Common side effects include:
+* [[Hypertension]]
+* [[Piloerection]] (goosebumps)
+* [[Urinary retention]]
+* [[Pruritus]] (itching)
-== Contraindications ==
+Patients are advised to monitor their blood pressure regularly to avoid excessive hypertension.
-Desglymidodrine is contraindicated in patients with:
-* Severe organic heart disease
+== Related Pages ==
-* Acute renal disease
-* Urinary retention
-* Pheochromocytoma
-== See Also ==
 * [[Midodrine]]
 * [[Orthostatic hypotension]]
-* [[Alpha-1 adrenergic receptor]]
+* [[Alpha-adrenergic agonist]]
+* [[Sympathetic nervous system]]
-== References ==
-* Smith, M. C., & Porth, C. M. (2008). ''Pathophysiology: Concepts of Altered Health States''. Lippincott Williams & Wilkins.
-* Freeman, R. (2008). ''Clinical Autonomic Disorders: Evaluation and Management''. Springer.
-[[Category:Adrenergic drugs]]
+[[Category:Alpha-adrenergic agonists]]
 [[Category:Vasoconstrictors]]
-[[Category:Prodrugs]]
+[[Category:Pharmacology]]